Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis

Inclusion Criteria: * Documented history of RA in agreement with ACR criteria * DMARD treatment for RA greater than or equal to 6 months, with a stable dose greater than or equal to 6 weeks prior to screening visit * Duration of morning stiffness greater than or equal to 45 minutes * greater than or equal to 4 swollen joints (out of 28) * greater than or equal to 4 tender joints (out of 28) Exclusion Criteria: * Suffering from another disease, which requires glucocorticoid treatment during the study period * Synovectomy within 4 months prior to study start * Use of glucocorticoids: * Continued use of systemic glucocorticoids within 4 weeks prior to screening visit * Intermittent use of glucocorticoids within 2 weeks prior to screening visit. * Joint injections within 6 weeks prior to screening visit * Topical glucocorticoids must be stopped at screening visit * Use of biologicals such as: tumor necrosis factor α (TNFα) inhibitors and other compounds within 5 serum half lives prior to screening visit * Pregnancy or nursing